华兰生物：关于收到药物临床试验批准通知书的公告

Core Viewpoint - On February 3, 2026, the company announced that it received the Clinical Trial Approval Notification from the National Medical Products Administration for its drug, Recombinant Exendin-4-Fc Fusion Protein Injection [2] Group 1 - The approval notification number is 2026LP00310 [2] - The drug is intended for clinical trials, indicating progress in the company's research and development efforts [2]